Article
Pro-Apoptotic Activity of Ruxolitinib Alone and in Combination with Hydroxyurea, Busulphan, and PI3K/mTOR Inhibitors in JAK2-Positive Human Cell Lines.
Advances in clinical and experimental medicine : official organ Wroclaw Medical University - 1 Jan 2000
Szymańska Joanna, Smolewski Piotr, Majchrzak Agata, Cebula-Obrzut Barbara, Chojnowski Krzysztof, Treliński Jacek
Abstract excerpt
BACKGROUND: The JAK2V617F mutation plays a crucial role in the pathogenesis of myeloproliferative neoplasms (MPNs). Inhibition of JAK2 activity by ruxolitinib (RX) results in growth inhibition and apoptosis of cells carrying the JAK2V617F mutation however the exact mechanisms regulating apoptosis have not been fully elucidated. OBJECTIVES: This study assessed the potential cytotoxicity of RX against JAK2-positive...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.